Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis. The hypothesis on which we are basing this study is that an endothelin receptor antagonist and disease modifying agent with antifibrotic properties will have additive influence on fibrosis, inhibit cellular and humoral hyperactivity and interfere with smooth muscle proliferation in the vessel wall. The combination of these two agents will also be the first regimen to address the heterogeneity of scleroderma manifestations including ILD, pulmonary arterial hypertension and skin manifestations. This study is currently recruiting participants. ClinicalTrials.gov. Identifier: NCT01093885. (Also see: Current Clinical Trials: Open Enrollment)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
No replies to this topic